CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows From (Used In) Operating Activities
Net Loss	$ (30,268,511)	$ (30,004,667)
Non-Cash Adjustments
Depreciation and Amortization	3,620,585	1,825,766
Stock-Based Compensation	9,797,274	12,016,334
Impairment of Patents and Trademarks	41,869	97,676
Change in Inventory Reserve for Obsolescence	485,183
(Increase) Decrease in Operating Assets
Accounts Receivable	(3,392,963)	(875,607)
Accrued Revenues in Excess of Billings	(168,146)	(393,250)
Employee Retention Credit Receivable	466,705
Inventories	(519,092)	(77,490)
Manufacturing Vendor Prepayments	377,642	73,330
Prepaid Expenses and Other Assets	(295,566)	(417,298)
Increase (Decrease) in Operating Liabilities
Accounts Payable	641,516	141,828
Accrued Expenses	(832,290)	(244,935)
Unearned Revenue	73,086	(3,425)
Income and Other Taxes Payable	(160,935)	(73,637)
Net Cash Flows Used in Operating Activities	(20,133,643)	(17,935,375)
Cash Flows From (Used In) Investing Activities
Purchases of Fixed Assets	(3,608,801)	(5,203,562)
Investments in Patents and Trademarks	(497,901)	(362,981)
Investments in Licenses, Intangibles and Other Assets	(9,500,000)	(6,125,000)
Investments in Software Development	(125,000)
Investments in Other Assets	(200,000)
Net Cash Flows Used in Investing Activities	(13,931,702)	(11,691,543)
Cash Flows From (Used In) Investing Activities
Proceeds from Exercise of Stock Options	21,196	48,505
Purchases of Treasury Stock	(470,757)	(251,057)
Net Cash Flows Used in Financing Activities	(449,561)	(202,552)
Net Decrease in Cash and Cash Equivalents	(34,514,906)	(29,829,470)
Cash and Cash Equivalents - Beginning of Period	72,563,943	120,203,873
Cash and Cash Equivalents - End of Period	38,049,037	90,374,403
Supplemental Disclosures
Unamortized Common Stock Expense included in Prepaid Expenses and Other Assets	1,126,777	1,204,942
Non-Cash Investment in Licenses	2,000,000	9,000,000
Stock-Based Compensation Expense - Expensed less Previously Issued	$ 133,584	$ (71,502)